Health Care

Regeneron’s new EU pediatric CSU approval for Dupixent and partnership with Telix in radiopharmaceuticals boost its precision‑medicine portfolio, creating fresh revenue streams and first‑mover advantage in unmet pediatric dermatology and targeted ca…

Pro Medicus extends a five‑year, $80 M deal with Northwestern Medicine, boosting AI imaging use, revenue and global reach while improving diagnostic speed and data security.

AbbVie’s Phase‑2 data show mirvetuximab soravtansine‑gynx is effective in platinum‑sensitive ovarian cancer, offering a biomarker‑driven, early‑line therapy that could boost market reach and investor sentiment.

Johnson & Johnson Q3 earnings show steady revenue growth, stronger margins and bullish guidance—highlighting a resilient pharma pipeline, new consumer products, and solid cash‑flow for shareholder returns.

Pro Medicus Ltd. remains a key Australian tech play amid Morgan Stanley’s valuation tightening—potential upside of 50‑100 % for risk‑tolerant investors seeking long‑term growth.

Regeneron’s latest earnings beat estimates, keep a low‑leveraged, liquid balance sheet, and a steady $0.94 quarterly dividend, showing solid health and room for future biotech growth.

Neurocrine Biosciences’ $2.9 billion acquisition of Soleno Therapeutics expands its neuro‑oncology pipeline, adding precision ADCs like SLO‑101 and SLO‑204 with promising early efficacy and a strong regulatory roadmap.

Zoetis Inc. shares dip amid market downturn, yet solid safety data, proven efficacy, and an active regulatory pipeline hint at future upside. Investors should watch upcoming updates for potential rebounds.

Veeva’s recent 3‑4% share dip and a director’s $235k Rule 144 sale signal insider sentiment shifts, liquidity resilience, and looming regulatory/competitive pressures—watch for deeper moves ahead.

Johnson & Johnson’s inclusion in a high‑yield ETF highlights its steady dividend track record and solid financial resilience, making it a top pick for income‑focused investors.